PharmaTimes.The trial, part of the European AIDS Vaccine Initiative, will feature 13 people between the ages of 18 and 65 who are not living with HIV and who researchers consider not at high risk of transmission.Participants will receive a dose of the vaccine — known as HIVconsvX, according to PharmaTimes — and then a booster dose four weeks after.The HIVconsvX vaccine is a mosaic vaccine and is designed to target the weakest areas of HIV in the body.A mosaic vaccine is one that combines parts of a variety of HIV strains that are put in one shot to begin an immune response, according to Johnson & Johnson.“An effective HIV vaccine has been elusive for 40 years,” Tomáš Hanke, the trial’s lead researcher and a professor of vaccine immunology.